The Globe and Mail reports in its Tuesday, Aug. 4, edition that as Apotex Health faces potential impacts from fresh threats of United States tariffs, analysts say the stock is still well-positioned for growth. The Globe's Sophia Bertuzzi writes that on Friday, Apotex traded around $37 a share -- more than 30 per cent higher than its debut trading price of $28. The stock rebounded late last week, after falling in the wake of Washington's plan to introduce tariffs on generic drug imports. Apotex's debut on June 10 was the largest life sciences and pharmaceutical initial public offering in Canadian history with it raising $1.3-billion. It's also the Toronto Stock Exchange's largest listing in five years. Apotex's stock performance has been a "standout," says National Bank Financial analyst Nathan Po. He rates Apotex "outperform." On July 21, the Trump administration announced its plan to impose 100-per-cent tariffs on generic pharmaceuticals starting Aug. 1, 2028, a figure that would rise to 200 per cent the next year. "Overall, the sustained expected buying pressure from indexers should help price performance in the coming months," Bank of Nova Scotia analyst Jean-Michael Gauthier wrote in a July 15 note.